Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking

被引:40
作者
Dobrinas, Maria [1 ]
Cornuz, Jacques [2 ]
Pedrido, Leticia [1 ]
Eap, Chin B. [1 ,3 ]
机构
[1] Univ Lausanne, Hosp Cery, CHUV, Ctr Psychiat Neurosci,Dept Psychiat,Unit Pharmaco, Prilly, Switzerland
[2] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[3] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland
关键词
cytochrome P4501A2; cytochrome P450 oxidoreductase; genetic polymorphism; inducibility; POR; smoking; ANTLEY-BIXLER-SYNDROME; P450; OXIDOREDUCTASE; MUTATIONS; STEROIDOGENESIS; METABOLISM; CLOZAPINE; CESSATION; VARIANTS; GENOTYPE; HUMANS;
D O I
10.1097/FPC.0b013e32834e9e1a
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
Background Cytochrome P4501A2 (CYP1A2) presents a high interindividual variability in its activity and also in its inducibility by smoking. Cytochrome P450 oxidoreductase (POR) is an electron transfer protein that catalyzes the activity of several cytochromes P450. We aimed to study the influence of POR genetic polymorphisms on CYP1A2 activity while smoking and after smoking cessation, as well as on CYP1A2 inducibility. Methods CYP1A2 activity was determined by the paraxanthine/caffeine ratio in 184 smokers and in 113 of these smokers who were abstinent during a 4-week period. Participants were genotyped for POR rs17148944G > A, rs10239977C > T, rs3815455C > T, rs2286823G > A, rs2302429G > A, and rs1057868C > T (POR*28) polymorphisms. Results While smoking, none of the tested POR polymorphisms showed a significant influence on CYP1A2 activity. After smoking cessation, significantly higher CYP1A2 activity was found in POR rs2302429A carriers (P = 0.038) and in carriers of rs17148944G-rs10239977C-rs3815455T-rs2286823Grs2302429A-rs1057868T haplotype (P = 0.038), whereas carriers of POR rs2286823A (P = 0.031) and of the rs17148944G-rs10239977C-rs3815455C-rs2286823Ars2302429G-rs1057868C haplotype (P = 0.031) had decreased CYP1A2 activity. In the complete regression model, only POR rs2302429G > A showed a significant effect (P = 0.017). No influence of POR genotypes or haplotypes was observed on the inducibility of CYP1A2. Conclusion POR genetic polymorphisms influence CYP1A2 basal but not induced activity and do not seem to influence CYP1A2 inducibility. Future work is warranted to identify other clinical and genetic factors that may explain the variability in CYP1A2 activity and inducibility by smoking. Pharmacogenetics and Genomics 22: 143-151 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 32 条
[1]
Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19 [J].
Agrawal, Vishal ;
Huang, Ningwu ;
Miller, Walter L. .
PHARMACOGENETICS AND GENOMICS, 2008, 18 (07) :569-576
[2]
[Anonymous], 2010, R LANG ENV STAT COMP
[3]
[Anonymous], 2011, NAT CTR BIOT INF DBS
[4]
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients [J].
Bondolfi, G ;
Morel, F ;
Crettol, SV ;
Rachid, F ;
Baumann, P ;
Eap, CB .
THERAPEUTIC DRUG MONITORING, 2005, 27 (04) :539-543
[5]
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine [J].
Carrillo, JA ;
Herráiz, AG ;
Ramos, SI ;
Gervasini, G ;
Vizcaíno, S ;
Benítez, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) :119-127
[6]
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility [J].
Dobrinas, M. ;
Cornuz, J. ;
Oneda, B. ;
Serra, M. Kohler ;
Puhl, M. ;
Eap, C. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (01) :117-125
[7]
Nonresponse to clozapine and ultrarapid CYP1A2 activity - Clinical data and analysis of CYP1A2 gene [J].
Eap, CB ;
Bender, S ;
Sirot, EJ ;
Cucchia, G ;
Jonzier-Perey, M ;
Baumann, P ;
Allorge, D ;
Broly, F .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (02) :214-219
[8]
Assessment of CYP1A2 activity in clinical practice: Why, how, and when? [J].
Faber, MS ;
Jetter, A ;
Fuhr, U .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 97 (03) :125-134
[9]
Flück CE, 2011, ENDOCR DEV, V20, P63, DOI 10.1159/000321221
[10]
Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism [J].
Flueck, Christa E. ;
Mullis, Primus E. ;
Pandey, Amit V. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 401 (01) :149-153